The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1

Bimmi Shrestha
Washington University School of Medicine in St. Louis

James D. Brien
Washington University School of Medicine in St. Louis

Soila Sukupolvi-Petty
Washington University School of Medicine in St. Louis

S. Kyle Austin
Washington University School of Medicine in St. Louis

Melissa A. Edeling
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Part of the Medicine and Health Sciences Commons

Recommended Citation
Shrestha, Bimmi; Brien, James D.; Sukupolvi-Petty, Soila; Austin, S. Kyle; Edeling, Melissa A.; Kim, Taekyung; O'Brien, Katie M.; Nelson, Christopher A.; Johnson, Syd; Fremont, Daved H.; and Diamond, Michael S., "The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1." PLoS Pathogens. 6,4. e1000823. (2010).
https://digitalcommons.wustl.edu/open_access_pubs/659

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1

Bimmi Shrestha1, James D. Brien1, Soila Sukupolvi-Petty1, S. Kyle Austin2, Melissa A. Edeling3, Taekyung Kim2, Katie M. O’Brien1, Christopher A. Nelson2, Syd Johnson3, Daved H. Fremont2,4,5, Michael S. Diamond1,2,5,6*

1 Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America, 2 Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America, 3 MacroGenics, Inc., Rockville, Maryland, United States of America, 4 Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri, United States of America, 5 The Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, Washington University School of Medicine, St. Louis, Missouri, United States of America, 6 Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America

Abstract

Antibody protection against flaviviruses is associated with the development of neutralizing antibodies against the viral envelope (E) protein. Prior studies with West Nile virus (WNV) identified therapeutic mouse and human monoclonal antibodies (MAbs) that recognized epitopes on domain III (DIII) of the E protein. To identify an analogous panel of neutralizing antibodies against DENV type-1 (DENV-1), we immunized mice with a genotype 2 strain of DENV-1 virus and generated 79 new MAbs, 16 of which strongly inhibited infection by the homologous virus and localized to DIII. Surprisingly, only two MAbs, DENV1-E105 and DENV1-E106, retained strong binding and neutralizing activity against all five DENV-1 genotypes. In an immunocompromised mouse model of infection, DENV1-E105 and DENV1-E106 exhibited therapeutic activity even when administered as a single dose four days after inoculation with a heterologous genotype 4 strain of DENV-1. Using epitope mapping and X-ray crystallographic analyses, we localized the neutralizing determinants for the strongly inhibitory MAbs to distinct regions of DIII. Interestingly, sequence variation in DIII alone failed to explain disparities in neutralizing potential of MAbs among different genotypes. Overall, our experiments define a complex structural epitope on DIII of DENV-1 that can be recognized by protective antibodies with therapeutic potential.

Introduction

Dengue virus (DENV) is a member of the Flaviviridae family and is related to the viruses that cause yellow fever, and the Japanese, St. Louis, and the West Nile encephalitides [1]. DENV infection after mosquito inoculation causes a spectrum of clinical disease ranging from a self-limited febrile illness (DF) to a life threatening hemorrhagic and capillary leak syndrome (Dengue Hemorrhagic Fever (DHF)/Dengue Shock Syndrome (DSS)). Globally, there is significant diversity among DENV strains, including four distinct serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) that differ at the amino acid level in the viral envelope proteins by 25 to 40 percent. There is additional complexity within a given DENV serotype, as genotypes vary further by up to ~6% and 3% at the nucleotide and amino acid levels, respectively [2,3]. At present, no approved antiviral treatment or vaccine is available, and therapy is supportive. DENV causes an estimated 25 to 100 million infections and 250,000 cases of DHF/DSS per year worldwide, with 2.5 billion people at risk [4,5].

DENV is an enveloped virus with a single-stranded, positive-sense RNA genome [6]. The 10.7 kilobase genome is translated as a single polyprotein, which is cleaved into three structural proteins (C, prM/M, E) and seven nonstructural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). The mature DENV virion has a well-organized outer protein shell, a lipid membrane bilayer, and a less-defined inner nucleocapsid core [7,8]. The ectodomains of DENV E proteins are assembled as dimers with each subunit comprised of three discrete domains [9–11]. Domain I (DI) is a central, eight-stranded β-barrel, which contains a single N-linked glycosylation site in most DENV strains. Domain II (DII) is a long, finger-like protrusion from DI and contains a second N-linked glycan that binds to DC-SIGN [12–13] and the highly conserved fusion peptide at its distal end. Domain III (DIII), which adopts an immunoglobulin-like fold, has been argued to contain a cell surface receptor recognition site [16–19]. Exposure to mildly acidic conditions in the trans-Golgi secretory pathway promotes virus maturation through a structural rearrangement of
Among the strongly neutralizing antibodies tested, only four were in a heterologous DENV-1 genotype 4 strain. The flavivirus E proteins and cleavage of prM to M by a furin-like protease [20,21] result in quasi-icosahedral symmetry.

Neutralizing MAbs against DENV reportedly have the greatest neutralizing activity [23,24] and some sub-complex specific MAbs, which recognize some but not all DENV serotypes, are also inhibitory [25–27]. Protection in animals by antibodies correlates generally with the degree of neutralizing activity in vitro [24,28–31]. Several type-specific strongly neutralizing antibodies against individual flaviviruses (e.g., West Nile virus (WNV), Japanese encephalitis virus (JEV), DENV-2, DENV-4, and yellow fever virus (YFV)) have been localized to epitopes in DI and DIII [26,29,32–42]. Based on their potency of neutralization and protection in vivo, anti-WNV humanized or human MAbs are in clinical development as candidate therapeutics [reviewed in [43]]. Although type-specific neutralizing MAbs against DENV have been characterized [44,45], few have been mapped to specific amino acids or structural determinants. To date, only two neutralizing IgM against DENV-1 were mapped by neutralization escape selection to amino acids E279 and E293, which lie outside of DIII [46].

To develop neutralizing MAbs against DENV-1 with possible clinical potential, mice were infected with a genotype 2 strain of a homologous DENV-1 virus, and boosted with recombinant DI-DII from the homologous DENV-1 strain. Initial immunization studies were performed with wild type BALB/c mice as done previously with WNV [29]. Because low neutralizing titers (<1/100) were achieved, mice were infected with the 16007 (genotype 2) prototype strain of DENV-1 and in some cases, boosted with recombinant DI from the homologous DENV-1 strain. Initial immunization studies were performed with wild type BALB/c mice as done previously with WNV [29]. Because low neutralizing titers (<1/100) were achieved, likely because of poor replication of DENV-1, we switched to an immunodeficient (IFN-γ−/−) strain in the C57BL/6 background. After screening more than 3,000 hybridoma clones as part of five independent fusions, we isolated and cloned 79 new MAbs that recognized cells infected with DENV-1 (Table S1).

All MAbs were initially tested semi-quantitatively for neutralization of the homologous DENV-1 strain by a single endpoint plaque reduction assay in Vero or BHK21-15 cells using neat hybridoma supernatant (~10 µg/ml). Of the MAbs generated, 18 showed no inhibitory activity (<15% neutralization), 45 had modest inhibitory activity (15–75% neutralization) and 16 were strongly inhibitory (>95% neutralizing). All MAbs were screened for E protein domain recognition using yeast that expressed DENV-1 DI-DII or DIII on their surface (Table S1: 14 bound to yeast expressing DI-DII, 53 recognized DIII, and the remaining 12 did not bind either DI-DII or DIII, indicating they recognized epitopes that are not present on the truncated yeast-expressed forms of DENV-1 E protein. All MAbs were tested for cross-reactivity using cells infected with different serotypes of DENV or WNV. Five of the fourteen DI-DII-specific MAbs and 26 of the 53 DIII-specific MAbs cross-reacted with other serotypes of DENV. Only 3 of the 78 MAbs bound all DENV serotypes and WNV. One of the neutralizing MAbs, DENV1-E50, was of the IgM isotype and not evaluated further here.

Characterization of strongly neutralizing MAbs against DENV-1

Studies with neutralizing mouse MAbs against DENV-2 defined a type-specific epitope on the lateral ridge of DIII (DIII-LR) and an adjacent more conserved β-strand termed the sub-complex-specific DIII A-strand epitope [25–27,41]. As our single endpoint titr neutralization experiments showed that all 15 inhibitory IgG MAbs localized to DIII of DENV-1, we analyzed their reactivity patterns with other strains. We found that 9 of the 15 neutralizing IgG MAbs were serotype-specific and showed no cross-reactivity to DENV-2, DENV-3, DENV-4 or WNV-infected cells. Five MAbs were sub-complex specific and bound some but not all DENV serotypes. Only one MAb, DENV1-E102, cross-reacted with all DENV serotypes but not with WNV-infected cells (Table 1).

Genotype-specific reactivity of anti-DENV-1 MAbs

As variation exists in the genetic composition of viruses within a given DENV serotype, an intra-serotype genotype classification system was developed [2,3], with a given genotype of a serotype
plaque reduction assay with 102 PFU of virus in Vero or BHK21-15 cells, depending on the strain (Table 2). In contrast, other DIII-specific non-neutralizing MAbs (e.g., DENVI-E91) showed reduced binding to several of the heterologous DENV-1 genotypes (Fig 1).

(b) Binding to different DENV-1 genotypes. To determine whether antibodies recognized different genotypes of DENV-1, we infected Raji-DC-SIGN-R or C6/36 cells (depending on permissiveness) with strains of the five different genotypes of DENV-1. Infected cells were incubated with hybridoma supernatants and analyzed by flow cytometry. All neutralizing MAbs tested efficiently recognized genotypes 1, 2, 4, and 5. However, a few of the MAbs (DENV1-E100, DENV1-E104, and DENV1-E111) showed reduced binding to cells infected with the genotype 3 strain (Table 2). In contrast, other DIII-specific non-neutralizing MAbs (e.g., DENVI-E91) showed reduced binding to several of the heterologous DENV-1 genotypes (Fig 1).

(b) Neutralizing potential of MAbs against different DENV-1 genotypes. Although most MAbs retained binding to cells infected with many of the genotypes, we questioned whether this translated into efficient cross-genotypic neutralization. A recent study of neutralization escape mutants with human MAbs against WNV showed that retention of binding did not necessarily sustain neutralizing activity [38]. To evaluate this, we assessed semi-quantitatively the inhibitory activity of hybridoma supernatants of 15 neutralizing MAbs against all five genotypes by a standard plaque reduction assay with 102 PFU of virus in Vero or BHK21-15 cells, depending on the strain (Table 3). Only 8 of 15 hybridoma supernatants neutralized strains from all five genotypes by greater than 90%, with three MAbs (DENVI-E103, DENVI-E105, and DENVI-E106) showing 100% neutralization of all genotypes. Several MAbs showed reduced neutralizing potential for individual genotypes even at the relatively high (~10 µg/ml) concentration of MAb used in the assay. For example, 9, 12, 12, and 14 MAbs neutralized infection by DENV genotypes 1, 3, 4, and 5, respectively. This was especially surprising for the genotype 1 strain as no appreciable reduction in binding to infected cells was observed (Table 2). As an example, DENVI-E104 showed relatively normal binding to the genotype 1 strain yet showed a 92% loss in neutralization activity. Some MAbs (DENVI-E100 and DENVI-E111), which had decreased binding to genotype 3 infected cells, also showed reduced inhibitory activity. Others (e.g., DENVI-E104) sustained normal inhibitory activity despite attenuated binding to fixed, permeabilized cells. Although more studies are necessary, this could reflect an epitope that is more sensitive to fixation in the context of recognition of specific genotypes.

To more rigorously characterize the neutralizing potency, we purified MAbs and assessed their inhibitory activity against the homologous genotype 2 (16007) strain in cell culture by performing a dose-response curve and determining the concentration of MAb (PRNT50, expressed here as ng/ml of antibody) that blocked plaque formation by 50% (Table 4). For the homologous genotype 2 16007 strain, 8 of 15 MAbs potently neutralized infection with PRNT50 values below 5 ng/ml. This value is significant as it is lower than that observed with our most inhibitory anti-WNV MAb (E16), which functions successfully as a post-exposure therapeutic agent [29,49,50]. Six other MAbs also showed strong inhibitory activity with PRNT50 values against 16007 of between 10 and 70 ng/ml. Only one MAb, E104 showed modest activity with a PRNT50 value of ~600 ng/ml.

Given our findings of genotype variation with respect to single endpoint neutralization using hybridoma supernatants, we repeat-
ed the dose-response curve analysis with a heterologous genotype 4 (West Pac-74) (Table 4). Surprisingly, the neutralizing activity was markedly decreased for all MAbs against the heterologous DENV-1 genotype (e.g., 6 to 9600-fold for DENV1-E100 and DENV1-E113, respectively). Only 2 MAbs, DENV1-E105 and DENV1-E106, retained strong neutralizing activity (≤20 ng/ml) against the West Pac-74 strain. Seven of 15 MAbs neutralized West-Pac74 poorly with PRNT50 values greater than 1 µg/ml of antibody. Thus, the neutralizing efficiency of several DIII-specific anti-

Table 2. MAbs binding to cells infected with different genotypes of DENV-1 virus.

| MAb          | Genotype 1 | Genotype 2 | Genotype 3 | Genotype 4 | Genotype 5 |
|--------------|------------|------------|------------|------------|------------|
|              | TVP-2130   | 16007      | TVP-5175   | West Pac-74| 3146-SL    |
| DENV1-E90    | 93         | 98         | 83         | 95         | 95         |
| DENV1-E95    | 94         | 98         | 81         | 95         | 95         |
| DENV1-E98    | 97         | 98         | 83         | 96         | 97         |
| DENV1-E99    | 96         | 98         | 84         | 96         | 97         |
| DENV1-E100   | 93         | 98         | 29         | 94         | 95         |
| DENV1-E101   | 93         | 98         | 82         | 95         | 96         |
| DENV1-E102   | 92         | 98         | 78         | 94         | 94         |
| DENV1-E103   | 94         | 98         | 83         | 95         | 95         |
| DENV1-E104   | 93         | 98         | 71         | 94         | 92         |
| DENV1-E105   | 89         | 98         | 75         | 94         | 95         |
| DENV1-E106   | 94         | 98         | 75         | 95         | 95         |
| DENV1-E108   | 93         | 98         | 77         | 95         | 94         |
| DENV1-E111   | 90         | 98         | 57         | 93         | 92         |
| DENV1-E112   | 94         | 98         | 81         | 95         | 95         |
| DENV1-E113   | 90         | 98         | 74         | 93         | 93         |

*Depending on the strain, Raji-DC-SIGN-R or C6/36 cells were infected with different genotypes of DENV-1 viruses. Fixed and permeabilized infected cells were incubated with the indicated MAbs (10 µg/ml) to determine the binding efficiency by flow cytometry. The data shown are the mean percentage of positive cells and derived from three independent experiments. Values underlined and italicized are statistically different (P<0.05).

Crystal structure of DENV-1 DIII and analysis of genotypic variation

To begin to understand the disparity in inhibitory potential of the DIII-specific neutralizing MAbs among different genotypes, we determined the X-ray crystal structure of recombinant DIII of the 16007 (genotype 2) strain at 2.25-Å resolution (Fig 2 and Fig 1). The data shown are representative histograms from two independent experiments with a neutralizing (DENV1-E106, upper panels) and non-neutralizing (DENV1-E91, lower panels) MAb.

doi:10.1371/journal.ppat.1000823.g001
increasing concentrations of purified MAb cells and 10^2 PFU of the indicated DENV-1 genotype. The data was derived from at least two independent assays performed in duplicate. Highlighted, italicized values indicate a genotypic specific reduction in neutralizing potential of a given MAb using neat hybridoma supernatant of greater than 20%.

doi:10.1371/journal.ppat.1000823.t003

Table 4. PRNT50 values of MAbs against a homologous and heterologous DENV-1 strain.

| MAb          | Genotype 1 | Genotype 2 | Genotype 3 | Genotype 4 | Genotype 5 |
|--------------|------------|------------|------------|------------|------------|
|              | TVP-2130   | 16007      | TVP-5175   | West Pac-74 | 3146-SL    |
| DENVI-E90    | 95         | 100        | 93         | 97         | 100        |
| DENVI-E95    | 93         | 100        | 94         | 72         | 93         |
| DENVI-E98    | 90         | 100        | 97         | 96         | 100        |
| DENVI-E99    | 95         | 100        | 97         | 96         | 100        |
| DENVI-E100   | 100        | 100        | 96         | 97         | 99         |
| DENVI-E101   | 98         | 100        | 100        | 92         | 100        |
| DENVI-E102   | 79         | 100        | 100        | 98         | 100        |
| DENVI-E103   | 100        | 100        | 100        | 100        | 100        |
| DENVI-E104   | 8          | 96         | 51         | 55         | 48         |
| DENVI-E105   | 100        | 100        | 100        | 100        | 100        |
| DENVI-E106   | 100        | 100        | 100        | 100        | 100        |
| DENVI-E108   | 69         | 100        | 86         | 97         | 95         |
| DENVI-E111   | 15         | 100        | 63         | 85         | 91         |
| DENVI-E112   | 46         | 100        | 76         | 79         | 94         |
| DENVI-E113   | 71         | 100        | 97         | 92         | 100        |

Neutralizing activity was determined semi-quantitatively by single endpoint plaque reduction assay on BHK21 or Vero cells with neat hybridoma supernatant cells and 10^2 PFU of the indicated DENV-1 genotype. The data was derived from at least two independent assays performed in duplicate. Highlighted, italicized values indicate a genotypic specific reduction in neutralizing potential of a given MAb using neat hybridoma supernatant of greater than 20%.

doi:10.1371/journal.ppat.1000823.t004

Table S2. Among the DENV-1 strains that represent the five different genotypes used in this study, variation in DIII was limited to nine residues, six of which were conservative substitutions (Fig 2 and Fig 3B). Four of the conservative substitutions (V/I380, L/V331, T/S339, and D/N341) are predicted to be partially or completely solvent inaccessible in the isolated DENV-1 DIII crystal structure and cryoelectron microscopy reconstruction of the mature virion [51], and thus, should not directly affect antibody engagement. In contrast, the conservative substitution K/R361 should be accessible due to its location in the DE loop. S/T397, the remaining conservative substitution is located after the G-strand in a region that links DIII with the first α-helix of the stem anchor motif. Of the three non-conservative substitutions, A/T369 is completely buried and although A/I/V345 is largely solvent accessible in the DIII crystal structure, it is likely buried in the virion according to cryoelectron microscopy reconstructions. The remaining non-conservative substitution (M/V297) occurs in the N-terminal linker region that connects to DI, which is solvent accessible in the DIII crystal structure, but less so in the mature virion structure. In summary, amino acid variation in DIII among the five different DENV-1 genotypes is modest, with the majority of changes being solvent inaccessible. Indeed, none of the observed genotypic variation occurs in residues previously implicated as critical to the creation of neutralizing antibody epitopes in DENV or related flaviviruses.

Epitope mapping of DIII neutralizing MAbs

On the basis of studies that mapped DIII-specific MAbs against WNV and DENV-2 [25–27,29,41], we initially used reverse genetics to engineer corresponding mutations (S305P, K307E, E309K, K310E, V324I, T329G, D330G, K361E, E362K, E384K, K385E, and K393E) on residues of the BC, DE, and FG loops and the A β-strand (A-strand) of DII of the genotype 2
The two most protective MAbs in vivo (see below), DENV1-E105 (type-specific) and DENV1-E106 (sub-complex specific), lost binding when residues on the BC (G328, T329 and D330), DE (K361E and E362K), and FG (K335) loops of the DIII-LR region were altered. Similarly, other protective MAbs (DENV1-E100 and DENV1-E103) also lost binding when residues in the BC or DE loop were altered. Type-specific MAbs (DENV1-E95, DENV1-E101, DENV1-E104, DENV1-E108, DENV1-E111, and DENV1-E112) that inhibited genotype 2 (16007) yet poorly neutralized the genotype 4 (West Pac-74) strain mapped to additional sites in DIII, DENV1-E95, DENV1-E104, DENV1-E108, and DENV1-E112 exhibited reduced binding with mutations in the G-strand (S390, W391, and K393) (Fig 3E) whereas DENV1-E101 was affected by changes in the N-terminal linker (T303) and BC-loop (G328, T329, and D330). Surprisingly, none of the mutations altered DENV1-E111 binding, and forward genetic screens with this MAb also failed to identify a loss-of-binding variant (data not shown), DENV1-E104, which showed the weakest neutralizing activity, localized to residues in the A (K310 and E311), F (E375), and G (S390 and W391) β-strands.

Because of analogous studies with DENV-2, we anticipated that sub-complex-specific and cross-reactive MAbs would recognize the A-strand epitope [25–27]. Indeed, mutation of S305, K307, E309, K310, and E311 reduced binding of several sub-complex MAbs (DENV1-E98, DENV1-E99, DENV1-E106, and DENV1-E113) in our panel. For the cross-reactive neutralizing MAb DENV1-E102, its epitope localized to residues in the N-terminal linker region (Y299, V300, and M301) and the BC loop (D330 and P332) (Fig 3F). Although Y299, M301, and P332 are highly conserved among strains of different DENV serotypes, V300 is specific for DENV-1 and D330 is present in DENV-1 and DENV-3; this may explain why DENV1-E102 fails to neutralize DENV-2 and DENV-3 efficiently (S. Sukupolvi-Petty, J. Brien, and M. Diamond, unpublished results).

Despite the extensive epitope mapping data (summarized in Fig 3B and 4), no structural explanation was readily apparent for the decrease in neutralization of the genotype 4 West Pac-74 strain by several antibodies. MAbs that showed markedly depressed neutralization of West Pac-74 localized to residues that were instead conserved among DENV-1 genotypes. To begin to address this, we evaluated whether individual MAbs differentially recognized DIII from 16007 or West Pac-74 strains when expressed on yeast; the DIII of these two strains differ by only two amino acids at positions 339 and 345 in the C strand and C'-loop (Fig 3B). Notably, all neutralizing MAbs equivalently recognized yeast displaying DIII of 16007 or West Pac-74 over a range of concentrations (Fig 5A, and data not shown). Thus, sequences differences in DIII of West Pac-74 and 16007 did not explain the differential patterns of neutralization. Because of this, we hypothesized that sequences variation in other domains of the West Pac-74 E protein could directly alter MAb binding or perhaps influence the display of DIII on the infectious virion. To test this, we performed a virion capture ELISA with 16007 and West Pac-74 viruses and selected MAbs having different neutralization profiles against the two strains (Fig 5B). DENV1-E98, which exhibited a ~50-fold reduction in neutralization showed little difference in binding over several concentrations of antibody. In contrast, DENV1-E111, which had ~4,000-fold less neutralizing activity, exhibited a depressed ability to bind West Pac-74 compared to 16007. Surprisingly, DENV1-E90 and DENV1-E113, which had ~600 to 9,600-fold differences in PRNT50 values with West Pac-74 compared to 16007 showed virtually no variation in binding in the capture ELISA. Thus, differential neutralization of genotypes 2 and 4 of DENV-1 could
Figure 3. Epitope localization of anti-DENV-1 MAbs. A. Flow cytometry histograms of loss-of-function DIII variants (V324I, T329G, D330G, K361E, E362K, and E384K) with individual neutralizing MAbs. Representative histograms are shown for the MAbs WNV E16 (negative control), DENV1-E95, DENV1-101, DENV1-103, and DENV1-106 with the wild type DIII and each of the variants. Data shown are representative of three independent experiments. B. Sequence alignment of different DENV-1 genotypes and mapping of neutralizing MAbs. The sequence and secondary structure of DIII from DENV-1 (strain 16007, genotype 2) E protein is aligned with other DENV-1 genotypes (genotype 1, strain TVP-2130; genotype 3, strain TVP 5175;
be explained by disparate binding to the virion for only a subset of MAbs. For MAbs like DENV1-E90 and DENV1-E113, the profile was similar to that observed with escape variants of a human anti-WNV MAb; in that case, mutations that abolished neutralizing activity did not appear to affect antibody binding to virus [48].

In vivo protection studies with neutralizing MAbs

Pre-exposure passive transfer of neutralizing MAbs against WNV, DENV-2, and DENV-4 protects against lethal infection in wild type and immunodeficient mice [24,29,52–56]. To confirm that neutralizing anti-DENV-1 MAbs protect in vivo and begin to explore the possibility for antibody therapy, we evaluated the efficacy of our panel of inhibitory MAbs against West Pac-74, the heterologous genotype 4 DENV-1 strain. The heterologous strain was selected for two reasons: (i) the West Pac-74 strain was the only DENV-1 isolate in our collection that caused 100% lethality in an intraperitoneal challenge model in AG129 mice; and (ii) a possible antibody therapeutic must demonstrate efficacy against DENV-1 strains of different genotypes.

A single dose (500 µg) of neutralizing MAbs against DENV-1 was administered as prophylaxis one day prior to infection with 10⁶ PFU of West Pac-74. Two MAbs (DENV1-E105 and DENV1-E106) protected 100% of mice compared to PBS or irrelevant MAb controls (P<0.0001), which had a 0% survival rate (Table 6). Three other MAbs (DENV1-E99, DENV1-E100, and DENV1-E103) exhibited strong yet incomplete protection with 60 to 80% survival rates. However, nine neutralizing MAbs (DENV1-E90, DENV1-E95, DENV1-E98, DENV1-E101, DENV1-E102, DENV1-E108, DENV1-E111, DENV1-E112 and DENV1-E113) protected inefficiently, with an 11 to 38% survival rate. Although the survival rate was relatively low for these MAbs, the mean time to death (MTD) was protracted (23±6.1 to 40±8.6 days) compared to untreated, infected mice (20±3.3 days). One neutralizing MAb, DENV1-E104 showed no protection against lethality although a longer MTD was observed. In general, the protective efficacy in vivo correlated with neutralizing antibody and structural recognition determinants: N-terminal region, light purple; lateral ridge (BC, DE, and FG loops), dark purple; A-strand, cyan; and F- and G-strand, green. C-F.

Localization of neutralizing epitopes on DENV-1 DIII as determined by yeast surface display. Structure of DENV-1 DIII (strain 16007) with amino acid residues marked in blue that significantly affect binding of neutralizing MAbs (C) DENV1-E106, (D) DENV1-E99, (E) DENV1-E95, and (F) DENV1-E102. doi:10.1371/journal.ppat.1000823.g003

Discussion

One primary goal of this study was to generate a collection of strongly neutralizing MAbs that would recognize virtually all DENV-1 strains and protect against infection as post-exposure therapy. In an attempt to achieve this, we generated a panel of 79 new MAbs against DENV-1 E protein. Although neutralizing antibodies can be generated against all three domains of the flavivirus E protein [29,32,42,46,52,55,57,58], we mapped the epitopes of the MAbs with the greatest inhibitory activity primarily to epitopes on DIII, analogous to that observed with MAbs against DENV-2 [25–27,41]. One surprising finding that has not been reported previously was the disparate neutralizing activity and protective potential of individual MAbs against different DENV-1 genotypes. In comparative studies with strains from genotype 2 and genotype 4, virtually all MAbs showed reduced (from 6 to 9,600-fold) PRNT50 values against the heterologous genotype. Because of this, few (5 of 15) MAbs protected as pre-exposure prophylaxis against infection by the heterologous DENV-1 genotype in AG129 mice, and only two (DENV1-E105 and DENV1-E106) showed utility as post-exposure therapy.

Although many DENV strains can cause a similar debilitating febrile illness in humans, there is significant genetic variation (25 to 40% amino acid difference for serotypes and up to 3% variation among genotypes within a serotype) and phenotypic difference in virulence among individual strains of specific serotypes and
Table 5. Summary of MAb binding to DENV-1 DIII mutants expressed on the surface of yeast.

| MAb | Y299N | V300M | V300E | M301I | T303I | S305P | K307E | E309K | K310E | E311K | V324I | G328E | T329G | D330G | P332S | K334N | Q340H | K343I | P356S | K361E | E362K | P364A | E370D | E375V | E384K | K385E | S390I | S390N | S390R | W391L | K393E | A404S |
|-----|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| E90 | 80    | 100   | 2     | 97    | 28    | 95    | 44    | 40    | 83    | 90    | 55    | 4     | 100   | 72    | 10    | 86    | 93    | 97    | 84    | 100   | 94    | 100   | 78    | 100   | 100   | 88    | 90    | 100   | 100   | 84    |
| E95 | 95    | 100   | 95    | 86    | 73    | 58    | 71    | 91    | 72    | 51    | 100   | 99    | 89    | 89    | 98    | 93    | 100   | 99    | 81    | 100   | 97    | 95    | 95    | 100   | 100   | 100   | 81    | 100   | 94    |
| E98 | 91    | 94    | 100   | 47    | 66    | 77    | 50    | 75    | 23    | 94    | 53    | 100   | 94    | 80    | 85    | 92    | 79    | 100   | 100   | 75    | 99    | <1    | <1    | <1    | <1    | <1    | <1    | 100   | 94    |
| E99 | 82    | 98    | 100   | 100   | 68    | 78    | 23    | 15    | 5     | 7     | 52    | 100   | 100   | 90    | 83    | 82    | 78    | 99    | 100   | 99    | 73    | 100   | 100   | 100   | 78    | 100   | 100   | 100   | <1    |
| E100| 100   | 100   | 37    | 31    | 100   | 73    | 1     | 93    | 33    | 100   | 28    | 100   | <1    | 2     | 42    | 100   | 100   | 82    | <1    | <1    | 100   | 48    | 100   | 90    | 53    | 100   | 100   | 80    | 100   | 39    |
| E101| 100   | 100   | 61    | 63    | 5     | 82    | 74    | 55    | 92    | 88    | 50    | 6     | <1    | 8     | 6     | 100   | 76    | 94    | 100   | 98    | 100   | 87    | 100   | 100   | 100   | 100   | 91    | 95    | 99    | 100   | 62    |
| E102| <1    | 1     | <1    | 2     | 86    | 71    | 72    | 47    | 66    | 81    | 49    | 9     | 99    | 15    | 2     | 5     | 71    | 100   | 67    | 100   | 100   | 88    | 95    | 70    | 100   | 69    | 73    | 61    | 81    | 100   | 71    |
| E103| 90    | 74    | 100   | 73    | 9     | 72    | 51    | 71    | 76    | 76    | 100   | <1    | <1    | <1    | 2     | 1     | 67    | 71    | 92    | 82    | 99    | 100   | 88    | 97    | 75    | 100   | 100   | 62    | 58    | 75    | 100   | 100   |
| E104| 86    | 91    | 73    | 58    | 99    | 100   | 100   | 73    | 15    | 4     | 100   | 49    | 100   | 26    | 38    | 89    | 65    | 100   | 100   | 45    | 48    | 100   | 98    | <1    | <1    | <1    | <1    | <1    | 100   | 98    | 100   | 100   |
| E105| 100   | 100   | 80    | 51    | 100   | 100   | 100   | 90    | 23    | 71    | 48    | 100   | 1     | 23    | 2     | 66    | 40    | 45    | 70    | 1     | 15    | 43    | 76    | 100   | 100   | 96    | 57    | 46    | 100   | 100   | 92    |
| E106| 83    | 79    | 85    | 57    | 65    | 76    | 75    | 100   | 16    | 100   | 100   | 100   | <1    | <1    | <1    | 1     | 22    | 74    | 42    | 67    | 100   | 3     | 3     | 3     | 5     | 67    | 100   | 37    | 12    | 56    | 60    | 91    | 100   | 68    |
| E108| 100   | 100   | 100   | 100   | 100   | 100   | 100   | 100   | 100   | 100   | <1    | <1    | <1    | <1    | <1    | <1    | <1    | <1    | 16    | 69    |
| E109| 95    | 100   | 99    | 92    | 36    | 98    | 95    | 100   | 90    | 22    | 100   | 100   | 100   | 96    | 5     | 33    | 5     | 62    | 97    |
| E111| 77    | 100   | 98    | 67    | 100   | 100   | 100   | 100   | 54    | 91    | 99    | 100   | 100   | 100   | 100   | 100   | 100   | 100   | 100   | 100   | 100   | 100   | 100   | 100   | 100   |
| E112| 28    | 100   | 100   | 100   | 94    | 100   | 100   | 100   | 98    | 98    | 100   | 100   | 100   | 99    | 63    | 73    | 80    | 76    | 100   | 100   | 100   | 100   | 100   | 99    | 41    | 8     | 78    | 100   | 100   |
| E113| 1     | 1     | <1    | 2     | 65    | 100   | 100   | 100   | 63    | 7     | 71    | 52    | 4     | 89    | 75    | 4     | 13    | 100   | 89    | 72    | 99    | 65    | 91    | 100   | 73    | 92    | 85    | 90    | 100   | 100   | 52    | 96    |

Values shown were achieved by dividing the total fluorescence product (percent positive population × mean linear fluorescence intensity) of a mutant for each individual antibody by the total fluorescence product of the wild type DIII×100. Values in bold indicate reductions in mAb binding of greater than or equal to 80% for a given mutation. Underlined values show a reduction between 50 and 79%. The results are the average of between three and five independent experiments for each mutant and each antibody.
genotypes [59–63]. Previous studies identified the lateral ridge and A-strand epitopes in DIII as targets of strongly neutralizing type-specific and sub-complex-specific neutralizing MAbs against DENV-2 and DENV-3 [26,27,41,64–67] and the fusion loop in DII as a recognition site for many cross-reactive neutralizing DENV MAbs [58,68,69]. In comparison, the serotype-specific DII-DIII hinge and dimer contact regions [48].

Although neutralizing anti-DENV-1 MAbs have been generated [44,45], few were localized to specific amino acids or structural domains. Two neutralizing IgM against DENV-1 were mapped by neutralization escape selection to amino acids E279 and E293, at the hinges between DI and DII or DI and DIII, respectively [46]. While our experiments establish that highly neutralizing antibodies recognize determinants in DIII of DENV-1, we do not rule out the existence of other epitopes in distinct regions. Rather, the panel of MAbs that we obtained may be skewed by the immunization protocol (boosting with recombinant DIII), primary screen, and genetic background of the animals, which influences the B cell repertoire. Indeed, for WNV we have recently identified strongly neutralizing anti-DENV-1 MAbs that abolishes the possibility of enhancement by abrogating binding to Fc-γ receptors.

Amino acid contact residues of neutralizing MAbs that react with DENV-2 or DENV-3 have been defined by analyzing neutralization escape mutants [40], chimeric DENV variants [89], site-specific DENV-2 mutants [68,90], peptide mapping [65,91,92], yeast surface display of variant E proteins [25,26,66], mutant recombinant proteins [27,41,67], and by co-crystallography of recombinant DENV proteins and Fab fragments of neutralizing MAbs [25]. Here, we used genetic strategies to generate mutant DIII of DENV-1 on yeast to map antibody recognition residues. The validity of the yeast surface display mapping for identifying critical contact residues has been confirmed by crystallographic studies that resolved the structural interface between WNV and DENV2 DIII Fab fragments [25,93] as well as DII-fusion loop specific Fab recognition [94]. For neutralizing type-specific DENV-2 MAbs that mapped to specific amino acid residues in DIII, the majority localized to residues in the BC and FG loops within the lateral ridge [26,41]. Our yeast mapping experiments confirm that the lateral ridge and A-strand on DIII are also recognized by strongly neutralizing anti-DENV-1 antibodies.

This is the first study that describes a post-exposure therapeutic effect of a MAb against any DENV strain in any animal model. In particular, DENV1-E105 and DENV1-E106, which neutralized all five DENV-1 genotypes showed efficacy when administered two or four days after infection of highly immunocompromised AG129 mice. In contrast, three other neutralizing MAbs (DENV1-E99, DENV1-E100, and DENV1-103) failed to protect when added a few days after infection even though they functioned as pre-exposure prophylaxis. Although prior studies demonstrated that anti-E MAbs protect against DENV infection in rodents and non-human primates [42,55,56,70,71], none have reported efficacy when added after infection. It is noteworthy that the two MAbs with the most neutralizing PRNT50 values were the ones with greatest therapeutic efficacy, suggesting, at least for strongly neutralizing MAbs of a given class, a correlation between in vitro and in vivo activity. It is unclear why therapeutic anti-DENV MAbs have not been previously described. Several post-exposure therapeutic MAbs or polyclonal antibody preparations against WNV, JEV, YFV, and tick-borne encephalitis virus have been reported [29,30,55,57,72–77], with some entering human clinical trials [43]. One speculation is that because viremia associated with DENV infection is several log greater than WNV [78–80], a condition of viral antigen excess occurs more rapidly in circulation leading to fewer antibody molecules binding to a given DENV virion. As neutralization is determined in part by the stoichiometry of antibody binding [81,82], only MAbs that can block infection at low fractional occupancy may be capable of neutralizing in vivo.

MAb-based therapies against DENV could be complicated by antibody-dependent enhancement of infection (ADE). Sub-neutralizing concentrations of antibody augment infection of Fc-γ receptor-expressing cells possibly by enhancing the efficiency of virus attachment or entry [83,84]. Thus, the administration of virus-specific MAbs could adversely impact the outcome of DENV infection. In non-human primates, passive transfer of sub-neutralizing concentrations of monoclonal or polyclonal antibody increased viremia although no change in disease status was observed [85,86]. Based on the possibility of ADE, MAb therapeutic against DENV in humans would appear to have considerable regulatory hurdles. However, recent studies with amino acid substitutions or deletions in the Fc region of recombinant anti-flavivirus antibodies prevented ADE in vitro and in vivo [86–88]. As such, studies are underway to engineer mutations into the Fc region of a humanized version of DENV1-E106 that abolishes the possibility of enhancement by abrogating binding to Fc-γ receptors.

The detailed mapping of neutralizing anti-DENV-1 MAbs identified two additional regions on DIII that comprised protective epitope(s): (a) DENV1-E102 and DENV1-E113, which react with
Figure 5. Binding of MAbs to DIII or virions of 16007 and West Pac-74. 

A. MAb binding to DIII of 16007 or West Pac-74 on yeast. Flow cytometry histograms of DIII of 16007 or West Pac-74 (different at residues 339 and 345) with neutralizing MAbs. Data shown are representative of two independent experiments. 

B. A capture ELISA was used to detect binding of MAbs to 16007 and West Pac-74 virions. Microtiter plates were coated with the indicated MAbs, incubated with $2 \times 10^6$ PFU of 16007 or West Pac-74 at room temperature, and with biotinylated anti-E MAbs. The data is an average of several separate experiments performed in duplicate, and error bars indicate standard deviation.

doi:10.1371/journal.ppat.1000823.g005
Table 6. In vivo protection of AG129 mice from West Pac-74 (genotype 4) after prophylaxis with neutralizing anti-DENV-1 MAbs.

| MAb       | Dose (μg/mouse) | Survival | MTD* ± SD | P valueb |
|------------|-----------------|----------|-----------|----------|
| No MAb     | 0               | 0/12     | 20±3      | N.S.     |
| WNV E16    | 500             | 0/5      | 18±2      | N.S.     |
| DENVI-E90  | 500             | 2/9      | 37±7      | <0.001   |
| DENVI-E95  | 500             | 2/10     | 36±11     | <0.0001  |
| DENVI-E98  | 500             | 2/8      | 34±14     | 0.002    |
| DENVI-E99  | 500             | 6/8      | 52±6      | <0.0001  |
| DENVI-E100 | 500             | 6/10     | 35±17     | <0.0001  |
| DENVI-E101 | 500             | 3/8      | 34±12     | 0.0005   |
| DENVI-E102 | 500             | 1/9      | 23±6      | 0.03     |
| DENVI-E103 | 500             | 7/10     | 29±14     | <0.0001  |
| DENVI-E104 | 500             | 0/8      | 26±8      | 0.03     |
| DENVI-E105 | 500             | 8/8      | NA        | <0.001   |
| DENVI-E106 | 500             | 10/10    | NA        | <0.001   |
| DENVI-E108 | 500             | 2/8      | 40±9      | <0.0001  |
| DENVI-E111 | 500             | 2/8      | 28±8      | 0.001    |
| DENVI-E112 | 500             | 1/8      | 25±11     | 0.03     |
| DENVI-E113 | 500             | 1/8      | 34±11     | 0.001    |

Mice were administered with 500 μg of indicated MAbs one day before infection with 10⁶ PFU of West Pac-74 by an IP route. Mice were monitored for survival for 60 days after infection. NS, not statistically different from PBS control.

aMean time to death (MTD) ± standard deviations (SD) refers to the mean time to death of the animals that succumbed to fatal infection. NA, indicates that no animals died in the presence of this MAb, and thus, the value was not calculated.

bP values were calculated using the log rank test of the Kaplan Meier survival curve by comparing the no antibody treated and antibody treated mice.

doi:10.1371/journal.ppat.1000823.t006

Table 6. In vivo protection of AG129 mice from West Pac-74 (genotype 4) after prophylaxis with neutralizing anti-DENV-1 MAbs.

Multiple DENV serotypes, showed an almost complete loss-of-binding with mutation of residues (Y299, V300, and M301) in the N-terminal linker region. This result is analogous to that described for neutralizing DENV-2 MAbs where the mutation M301G abolished reactivity of five complex-specific and seven serotype-specific MAbs [27,41]. The binding of the N-terminal linker by MAbs against WNV has been speculated to contribute to neutralization by inhibiting the significant rotation of DIII during the dimer to trimer transition [93]. (b) DENVI-E95, DENVI-E98, DENVI-E104, DENVI-E108, and DENVI-E112 exhibited loss of binding when residues (S390, W391, and K393) in the G-strand were changed. As the G-strand of the DIII is solvent accessible on virions of distinct genotype; (c) individual loss-of-function mutations identified by yeast display do not necessarily represent the complete footprint on DIII of bound antibody; (d) because of sequence variation outside of DIII, the E protein of different DENV-1 genotypes may pack differently on the virion. Some components of an epitope for a given MAb may be differentially exposed on virions of distinct genotype; (e) neutralizing potential showed reduced binding to West Pac-74, but others (DENVI-E90 and DENVI-E113) did not. This was corroborated in surface plasmon resonance studies, which showed an ~10-fold decrease in the K_D of binding of DENVI-E111 for West Pac-74 DIII (K. Austin, M. Diamond, D. Fremont, unpublished results).

Although our most strongly neutralizing MAbs localized to DIII of DENV-1, these antibodies were derived from immunodeficient mice, which may not necessarily reflect the neutralizing antibody response in humans. The antibody repertoire against DENV-1 or other serotypes in humans remains unknown, as B cell profiling at the epitope level has not been performed. Nonetheless, recent studies suggest that the humoral response against flaviviruses in humans may be directed away from DIII neutralizing epitopes of heterologous DENV serotypes. Notably, we did not observe detectable lateral ridge and A-strand epitopes, DIII-specific antibodies comprised only a small fraction of the total antibody in DENV immune sera [96,97]; whether these antibodies contribute to DENV neutralization in vivo remains controversial. Because highly neutralizing antibodies against DIII of DENV-1, DENV-2, and DENV-3 map to the lateral ridge and A-strand epitopes, DIII-based vaccines [98–101] that skew the humoral response have the potential to elicit highly protective responses.

One intriguing finding was that the disparate neutralizing activity of individual MAbs against different DENV-1 genotypes. Infection with one DENV serotype is believed to confer long-term immunity against strains of the homologous but not heterologous DENV serotypes. Based on this, we assumed it would be straightforward to generate DIII-specific therapeutic MAbs that neutralized all five genotypes within the DENV-1 serotype. Indeed, there are limited amino acid changes in DIII among DENV-1 genotypes with a maximum difference of seven amino acids, with genotype 5 the most diverse although the changes are largely conserved and reside in solvent inaccessible regions. Nonetheless, several MAbs in the panel exhibited markedly depressed neutralizing activity against the heterologous West Pac-74 strain. This was perplexing given that the 16007 and West Pac-74 strains differ in DIII by two amino acids, which were not coincident with our epitope mapping data: a T->S change at residue 339 in the C-strand and an A->V change at residue 345 in the C-C' loop. Indeed, in comparative binding assays with 16007 and West Pac-74 DIII on yeast, no obvious difference in binding at saturating concentrations of MAb was observed. When studies were repeated with selected MAbs in a virus capture ELISA, one MAb (DENVI-E111) with disparate neutralizing potential showed reduced binding to West Pac-74, but others (DENVI-E90 and DENVI-E113) did not. This was corroborated in surface plasmon resonance studies, which showed an ~10-fold decrease in the K_D of binding of DENVI-E111 for West Pac-74 DIII (K. Austin, M. Diamond, D. Fremont, unpublished results).

Although further structural studies are warranted, we propose four hypotheses to explain these results: (a) similar to findings with a recently characterized human anti-WNV MAb [48], mutations that abrogate neutralizing activity do not always reduce measurable antibody binding to the virion; (b) because of sequence variation outside of DIII, the E protein of different DENV-1 genotypes may pack differently on the virion. Some components of an epitope for a given MAb may be differentially exposed on virions of distinct genotype; (c) individual loss-of-function mutations identified by yeast display do not necessarily represent the complete footprint on DIII of bound antibody, as mutation of other residues may have allosteric effects; or (d) neutralizing anti-DENV-1 MAbs in our panel may have additional amino acid contacts outside of DIII that vary among the DENV-1 genotypes. Notably, we did not observe detectable binding of any the DIII-specific neutralizing MAbs to a DI-DIII protein displayed on yeast (data not shown). Structural studies with Fab-E protein or Fab-virion complexes will be required to address these possibilities.
This has potential implications for assessing the breadth of the protective efficacy of tetravalent DENV vaccines, which are in advanced clinical trials. In addition to evaluating protection against other serotypes, it may be critical to assess whether antibody responses against the vaccine strain of a given serotype neutralize infection of heterologous genotypes equivalently.

**Materials and Methods**

**Cells and viruses**

Vero, BHK21-15 and Raji-DC-SIGN-R cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Omega Scientific) and antibiotics (penicillin G and streptomycin) at 37°C in a 5% CO₂ incubator.
Strains from all five genotypes of DENV-1 included: TVP-2130 (genotype 1), 16007 (genotype 2), TVP-5175 (genotype 3), Western Pacific-74 (genotype 4) and 3146 Sri Lanka (genotype 5). TVP-2130 and TVP-5175 were obtained from Dr. Robert Tesh and the World Reference Center for Emerging Viruses and Arboviruses (University of Texas Medical Branch, Galveston, TX). Western Pacific-74 (West Pac-74) and the 3146 Sri Lanka strain were obtained from Drs. Stephen Whitehead (NIADDK, NIH, Bethesda, MD) and Rebeca Rico-Hesse (Southwest Foundation for Biomedical Research, San Antonio, Texas), respectively. Strains corresponding to other DENV serotypes were also used: 16681 (DENV-2), 16652 (DENV-3), and H241 (DENV-4). All viruses were amplified in C6/36 Aedes albopictus cells according to previously described protocols [26].

Generation, purification, and labeling of anti-DENV-1 MAbs

MAbs were generated essentially as described [29] after performing several independent splenocyte-myeloma fusions. To generate anti-DENV-1 MAbs, IFN-γR−/− C57BL/6 mice were infected with 10^3 PFU of DENV-1 strain 16007 (genotype 2) via an intraperitoneal route and re-challenged two weeks later with the same strain. Mice with serum having the highest neutralizing titer (≥1/1500) were immunized with purified DIII (50 µg, strain 16007) in PBS as a final intravenous boost. Three days later splenocytes were fused to P3X63Ag8.33 myeloma cells [102]. MAbs were subcloned by limiting dilution, isotyped (Pierce Rapid ELISA Kit), and purified using protein A affinity chromatography (Invitrogen). For library sorting experiments, MAbs were labeled with Alexa Fluor 647 or Alexa Fluor 488, using a MAb labeling kit (Molecular Probes) according to the manufacturer’s instructions.

In vitro neutralization assay

Plaque reduction neutralization titer (PRNT) assays were performed with the indicated DENV-1 strains with MAbs or serum on BHK21-15 cells as described previously [26,80]. PRNT50 values were determined using non-linear regression analysis (Graph Pad Prism4).

Cloning and expression of DIII of DENV-1 E protein

A cDNA encoding DENV-1 DIII (strain 16007, residues 293 to 400) of the 16007 strain was amplified from viral RNA by reverse transcriptase and high-fidelity Platinum Taq polymerase chain reaction (PCR) according to the manufacturer’s instructions (Invitrogen). The PCR product was cloned into the pET21a bacterial expression plasmid (EMD Biosciences) using flanking NdeI and XhoI restriction sites, sequenced, and then expressed in BL21 Codon Plus (Stratagene) E. coli. Inclusion bodies containing insoluble aggregates were denatured in the presence of 6 M guanidine hydrochloride and 20 mM β-mercaptoethanol and refolded in the presence of 400 mM L-arginine, 100 mM Tris-base (pH 8.0), 2 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, and 5 and 0.5 mM reduced and oxidized glutathione, respectively. Refolded protein was separated from aggregates on a Superdex 75 or 200, 16/60 size exclusion column using fast-protein liquid chromatography (GE Healthcare).

X-ray crystallographic structure determination of DV1 DIII

DENV-1 DIII was crystallized by vapor diffusion in hanging drops at 20°C at a concentration of 14 mg/ml. The drop contained equal parts protein and well solution composed of 0.1 M imidazole-HCl at pH 7.5, 0.2 M lithium sulfate, and 30% (w/v) polyethylene glycol 3000. Crystals were cryoprotected after a soak in well solution containing 15% glycerol before rapid cooling in a nitrogen gas stream. Data was collected at ALS beamline 4.2.2 (Lawrence Berkeley Laboratories, Berkeley, CA) at 293 K and at a wavelength of 1.29 Å using a CCD detector. The data were processed and scaled in HKL-3000 [103]. Crystallographic phasing was obtained by molecular replacement using the program Phaser [104] and the corresponding DIII fragment from DV2 (PDB accession 1OAN) as a search model. The resulting atomic model was iteratively built in O [105] and refined in REFMAC [106]. The final model with one DENV1 DIII monomer per asymmetric unit has been refined to 2.25Å resolution and contains 103 amino acid residues (residues 296 to 399 of DIII) and 53 water molecules. The DENV1 DIII domain is similar in structure to that reported for the post-fusion DENV-1 E ectodomain trimer (3G7T) [11] with a root-mean-square difference of 1.6 Å between Cα atom positions for equivalent core residues 296 through 394 [107]. The coordinates and diffraction data have been deposited in the RCSB with accession number 3IRC.

Domain mapping by yeast surface display

The DNA fragments encoding amino acid residues 1 to 293 (DI-DII) and 294 to 409 (DIII) of DENV-1 E protein were amplified from the DENV-1 strain 16007 or West Pac-74 by RT-PCR with BamHI and XhoI sites added at the 5’ and 3’ end, respectively. The PCR products were cloned as downstream fusions to Aga2 and Xpress epitope tag genes in the yeast surface display vector pYD1 (Invitrogen), under the control of an
upstream GAL1 promoter. These constructs were transformed into Saccharomyces cerevisiae strain EBY100 [108,109] using E. Coli transformed into XL1-Blue competent (Stratagene), or isolated from independent ultracompetent cells (Stratagene). The colonies were pooled and transformed into yeast cells as described above. In some instances, additional site-specific mutations were engineered into DENV-1 DIII by a reverse genetic approach using the Quick Change II Mutagenesis Kit (Stratagene).

For individual MAbs, the DENV-1 DIII mutant library was screened according to a previously described protocol [29]. To identify yeast that had selectively lost binding to a given MAb, the library was stained with an individual Alexa Fluor 647 conjugated MAbs for 30 min on ice. To control for surface expression of appropriately folded DIII of DENV-1, yeast cells were subsequently stained for 30 min on ice with an Alexa Fluor 488-conjugated pool of DIII-specific MAbs (DENV1-E90, DENV1-E95, DENV1-E99, DENV1- E111, DENV1-E112, and DENV1-E113), and then processed by flow cytometry. The population that was single MAb negative but pool oligoclonal positive was selected and sorted. After four to five rounds of sorting, yeast were plated and individual colonies were tested for binding to individual MAbs by flow cytometry. For clones that had lost binding to the desired MAb of interest, the plasmid was recovered using a Zymoprep yeast miniprep kit (Zymo Research), transformed into XL1-Blue competent E. Coli (Stratagene), purified using a QIAprep spin miniprep kit (Qiagen), and sequenced.

Immunostaining of DENV-infected cells

For the study of binding of DENV-1 MAbs to different DENV strains, Raji-DC-SIGN-R or C6/36 cells were infected with different DENV strains at a multiplicity of infection (MOI) of 1. Depending on the DENV-1 strain, Raji-DC-SIGN-R cells were harvested at 48 or 96 hours and C6/36 cells were harvested at day 7 after infection. Cells were washed, fixed in PBS with 4% paraformaldehyde, and permeabilized in Hanks’ balanced salt solution (HBSS) supplemented with 10 mM HEPES (pH 7.3), 0.1% (w/v) saponin (Sigma), and 0.02% NaN3. The cells were then incubated with MAbs for 30 minutes on ice, washed and incubated subsequently with an Alexa Fluor 647-conjugated goat anti-mouse IgG (Molecular Probes). After 30 minutes, cells were washed and fixed in PBS with 1% paraformaldehyde and analyzed by flow cytometry. To test whether DENV-1 MAbs cross-reacted with more distantly related flaviviruses, infection and staining experiments were performed with WNV (strain 3000.0259) and Raji-DC-SIGN-R cells as described previously [52].

DENV-1 virus capture ELISA

The capture ELISA for DENV-1 was based on a published assay for WNV with modifications [48]. Briefly, anti-DENV-1 MAbs were coated at indicated concentrations on MaxiSorp (Nunc) polystyrene 96-well microtiter plates in a sodium carbonate (pH 9.3) buffer. Plates were washed three times in ELISA wash buffer (PBS with 0.02% Tween 20) and blocked for 1 hour at 37°C with ELISA block buffer (PBS, 2% bovine serum albumin, and 0.02% Tween 20). DENV-1 virions (2.5 to 5.0×10^6 PFU of strain 16007 or West Pac-74) diluted in DMEM with 10% heat-inactivated FBS were captured on plates coated with anti-DENV-1 MAbs for 2 hours at room temperature. Plates were rinsed five times in wash buffer and then incubated with biotinylated 4G2 (1 µg/ml, respectively diluted in ELISA block buffer), which recognizes the fusion loop peptide in DII, for 1 hour at room temperature. Plates were washed again five times and then sequentially incubated with 2 µg/ml of horseradish peroxidase-conjugated streptavidin (Vector Laboratories) and tetramethyl-benzidine substrate (Dako). The reaction was stopped with the addition of 2 N H2SO4 to the medium, and emission (450 nm) was read using an iMark microplate reader (Bio-Rad).

Mouse experiments

All mouse studies were approved and performed according to the guidelines of the Washington University School of Medicine Animal Safety Committee. IFN-γR−/− × γR−/− mice on the 129 Sv background (AG129 mice) were a gift from Dr. Skip Virgin (Washington University School of Medicine) and bred in a pathogen-free barrier facility. In prophylaxis experiments, AG129 mice were administered a single dose of individual MAbs one day before infection. Subsequently, mice were challenged with West Pac-74 (genotype 4, 10^6 PFU) by an IP route and morbidity and mortality were monitored for 60 days. In post-exposure therapeutic experiments, a single 500 µg dose of MAb dose was administered by IP injection two or four days after infection with 10^6 PFU of West Pac-74.

Mapping of mutations onto the DENV-1 DIII crystal structure

Figures were prepared using the atomic coordinates of DENV-1 DIII (PDB accession number 3IRC) using the programs CCP4MG [110]. The alignment of DENV-1 DIII from different genotypes was created with the program ALSCRIPT [111].

Statistical analysis

All data were analyzed using Prism software (GraphPad software). For survival analysis, Kaplan-Meier survival curves were analyzed by log-rank test. For neutralization assays an unpaired student’s T-test was used to determine significance.

Supporting Information

Table S1 Profile of DENV-1 MAbs

| Found at: | doi:10.1371/journal.ppat.1000823.s001 | 0.06 MB DOC |

Table S2 Summary of Data Collection and Refinement

| Found at: | doi:10.1371/journal.ppat.1000823.s002 | 0.03 MB DOC |
Acknowledgments

The authors thank R. Rico-Hesse and R. Tesh for generously providing DENV-1 strains, H. Virgin for the AG129 mice, and T. Pierson for constructive discussions and critical comments on the manuscript.

Author Contributions

Conceived and designed the experiments: BS JDB SSP SKA MAE MAE TK CAN SJ DHF MSD. Performed the experiments: BS JDB SSP SKA MAE TK CAN SJ DHF MSD. Analyzed the data: BS JDB SSP SKA MAE TK CAN SJ DHF MSD. Wrote the paper: BS JDB CAN SJ DHF MSD.

References

1. Burke DS, Monath TP (2001) Flaviviruses. In: Knipe DM, Howley PM, eds. Fields Virology. Fourth Edition ed. Philadelphia: Lippincott Williams & Wilkins. pp 1043–1125.

2. Rico-Hesse R (1990) Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology 174: 479–493.

3. Holmes EC, Tawdhy SS (2003) The origin, emergence and evolutionary genetics of dengue virus. Infect Genet Evol 3: 19–20.

4. Landsdow SE (1980) Pathogenesis of dengue: challenges to molecular biology. Science 239: 476–481.

5. Monath TP (1994) Dengue: the risk to developed and developing countries. Proc Natl Acad Sci U S A 91: 2393–2396.

6. Chambers TJ, Hahn CS, Galler R, Race CM (1990) Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44: 649–688.

7. Kuhn RJ, Zhang W, Rossmann MG, Petney SV, Corder J, et al. (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 106: 717–725.

8. Zhang Y, Corder J, Chipman PR, Zhang W, Petney SV, et al. (2003) Structures of immature flavivirus particles. Emb J Exp 22: 2604–2613.

9. Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100: 6906–6911.

10. Modis Y, Ogata S, Clements D, Harrison SC (2005) Variable surface epitopes in the crystal structure of dengue type 3 envelope glycoprotein. J Virol 79: 1225–1231.

11. Nayak V, Desau M, Kucera K, Anthony K, Ledizet M, et al. (2009) Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. J Virol 83: 4338–4344.

12. Mondotte JA, Lozach PY, Amara A, Gannak MM (2007) Essential Role of Dengue Virus Envelope Protein N-Glycosylation at Asparagine-67 during Viral Propagation. J Virol 81: 7136–7148.

13. Pokihyseva E, Zhang Y, Battisti AJ, Bator-Kelly CM, Chipman PR, et al. (2006) Cryo-EM reconstruction of dengue virus in complex with the epitope-recognizing domain of DSIGN. Cell 124: 485–493.

14. Tassaneintriphop B, Burgess T, Granelli-Piperno A, Trumpfheller C, Finke J, et al. (2003) DSIGN (C6) mediates dengue virus infection of human dendritic cells. J Exp Med 197: 823–829.

15. Thirumalai S, Andrey ES, Almevver R, Aman S, Schwartz O, Fieschi F, et al. (2003) Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 4: 723–728.

16. Rey FA, Heinz FX, Mandi C, Kanz C, Harrison SC (1995) The envelope glycoprotein of tick-borne encephalitis virus at 2 Angstrom resolution. Nature 375: 291–298.

17. Bhadrwaj S, Holbrook M, Shope RE, Barrett AD, Watowich SJ (2001) Biophysical characterization and vectorial activity of domain III of the tick-borne flavivirus envelope protein. J Virol 75: 4002–4007.

18. Volk DE, Beasley DW, Kuhn RJ, Diamond MS (2005) Variable surface epitopes of Flavivirus. In: Fields Virology. Fourth Edition ed. Philadelphia: Lippincott Williams & Wilkins. pp 1281–1266.

19. Gromoski GD, Barrett AD (2008) Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82: 8828–8837.

20. Diamond MS, Sisti E, Friend L, Shrestha B, Higgs S, et al. (2003) Induced immune protection against lethal West Nile Virus infection. J Exp Med 198: 1–11.

21. Oliphant T, Engle M, Nybakken G, Doane C, Johnson S, et al. (2005) Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nature Medicine 11: 522–530.

22. Brandring MW, Schäublin J, Walsh EE, Beussel M (1966) Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol 67: 229–234.

23. Gould EA, Buckley A, Barrett AD, Cammack N (1986) Neutralizing (54k) and non-neutralizing (54k and 48k) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol 67 (Pt 3): 391–395.

24. Beasley DW, Barrett AD (2002) Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 76: 13097–13100.

25. Crill WD, Roehrig JT (2001) Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75: 7769–7773.

26. Roehrig JT, Bolin RA, Kelly RG (1998) Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaicas. Virology 246: 317–326.

27. Perez MD, Pierson TC, McLennet D, Hamu SL, Puffer BA, et al. (2005) Neutralization of antibodies to West Nile virus. Virology 356: 70–82.

28. Cecilia D, Gould EA (1991) Nucleotide changes responsible for loss of neurovirulence in Japanese encephalitis virus neutralization-resistant mutants. Virology 180: 71–77.

29. Seif SA, Morita K, Matsuo S, Hasabe F, Igarashi A (1995) Finer mapping of neutralizing epitope(s) on the C-terminal of Japanese encephalitis virus E protein expressed in recombinant Escherichia coli system. Vaccine 13: 1515–1522.

30. Wu SC, Lian WC, Hsu LC, Liao MY (1997) Japanese encephalitis virus antigen variants with characteristic differences in neutralization resistance and mouse virulence. Virus Res 51: 173–181.

31. Schäublin J, Chapman S, Nestorowicz A, Race CM, Ginocchio CE, et al. (1996) Replication of yellow fever virus in the mouse central nervous system: comparison of neuroadapted and non-neuroadapted virus and partial sequence of the neuroadapted strain. J Gen Virol 77: (Pt 6): 1277–1283.

32. Lin B, Parrish CR, Murray JM, Wright PJ (1994) Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 202: 883–890.

33. Gromoski GD, Barrett AD (2007) Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366: 387–397.

34. Lai CJ, Gonzalez AP, Men R, Wernly C, Donou O, et al. (2007) Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J Virol 81: 12766–12774.

35. Diamond MS (2009) Progress on the development of therapies against West Nile virus. Antiviral Res 83: 214–227.

36. Simantini E, Banerjee K (1995) Epitope mapping of dengue 1 virus E glycoprotein using monoclonal antibodies. Arch Virol 140: 1277–1273.

37. Chen YC, Huang HW, Lin CT, Chen YF, King CC, et al. (2007) Generation and characterization of neutralized monoclonal antibodies against dengue virus type 1 for epitope mapping and serological detection by epitope-based peptide antigens. Clin Vaccine Immunol 14: 404–411.

38. Beasley DW, Aaksung JG (2001) Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies. Virology 279: 447–458.

39. Gonzalez AP, Escalante AA, Pujol FH, Ludert JE, Towar D, et al. (2002) Diversity and evolution of the envelope gene of dengue virus type 1. Virology 303: 110–119.

40. Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, et al. (2009) Human Monoclonal Antibodies Induced by Natural Infection Against West Nile Virus Neutralize at a Post-Attachment Step. J Virol 83: 6494–6507.

41. Morens JD, Seldibarhan V, Olsen AL, Roper GV, Wang H, et al. (2006) Humanized monoclonal antibody against West Nile virus E protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis 194: 1300–1308.
78. Vauthun DW, Green S, Kalyanarangoon S, Insin BL, Nimmanmetha S, et al. (2000) Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity. J Infect Dis 181: 2–9.
79. Xiao SY, Guzman H, Zhang H, Travassos da Rosa AP, Tesh RB (2001) West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis 7: 714–721.
80. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M (2003) B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 77: 2578–2586.
81. Person TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, et al. (2007) The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host and Microbe 1: 135–145.
82. Klaase PJ (2007) Modeling the envelope glycoprotein trimers per virion participate in human immunodeficiency virus infection and its neutralization by antibody. Virolology 369: 245–262.
83. Collins S, Porterfield J (1984) Flavivirus infection enhancement in macrophages: radioisotope and biologic studies on the effect of antibody and viral fate. J Gen Virol 65: 1261–1272.
84. Halstead SB (1994) Antibody-dependent enhancement of infection: a mechanism for indirect virus entry into cells. Cellular Receptors for Animal Viruses. Cold Spring Harbor: Cold Spring Harbor Laboratory Press. pp 495–516.
85. Halstead SB (1979) In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140: 527–535.
86. González AP, Engle RE, St Claire M, Purcell RH, Lai CJ (2007) Monoclonal antibody treatment for West Nile virus infection in mice. J Infect Dis 188: 95–112.
87. Ghimelb E, Ansar-Solihin C, Johnson S, Engle M, Fremont DH, et al. (2008) Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host and Microbe 2: 417–426.
88. Babu SJ, Williams KL, Lachica R, Flores D, Kyle JL, et al. (2010) Lethal antibody enhancement is prevalent of disease in mice. Proc Natl Acad Sci U S A 107: 4922–4927.
89. Morrey JD, Siddharthan V, Olsen AL, Wang H, Julander JG, et al. (2007) Mapping of a dengue virus neutralizing epitope critical for the infectivity of all four serotypes. J Gen Virol 88: 2387–2397.
90. Chen Z, Liu LM, Gao N, Xu XF, Zhang JL, et al. (2009) Passive protection of mice, testing J Virol 73: 783–786.
91. Armstrong PM, Rico-Hesse R (2003) Efficiency of dengue serotype 2 virus strains to infect and disseminate in Aedes aegypti. Am J Trop Med Hyg 69: 359–344.
92. Armstrong PM, Rico-Hesse R (2003) Microevolution and virulence of dengue viruses. Adv Virus Res 59: 315–341.
93. Lissow A, Hartly F, Petet V, Bedouelle H (2007) Mapping to completeness and transplantanation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus. J Gen Virol 88: 2387–2397.
94. Thullier P, Demangel C, Bedouelle H, Megret F, Jouan A, et al. (2001) Virus structural differences that correlate with pathogenesis of West Nile virus infection. Cell Host and Microbe 1: 135–145.
95. Thullier P, Demangel C, Bedouelle H, Megret F, Jouan A, et al. (2001) Virus structural differences that correlate with pathogenesis of West Nile virus infection. Cell Host and Microbe 1: 135–145.
96. Valdes I, Bernardo L, Gil L, Pavon A, Lazo L, et al. (2009) A novel fusion-loop specific antibody. EMBO J 28: 3269–3276.
97. Chery MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, et al. (2009) Structural basis for the preferential binding of immature flaviviruses by a fusion-loop specific antibody. EMBO 28: 3269–3276.
98. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, et al. (2007) The Induction of Epitope-Specific Neutralizing Antibodies against West Nile virus. J Virol 81: 11828–11839.
99. Halstead SB (1979) In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140: 527–535.
100. González AP, Engle RE, St Claire M, Purcell RH, Lai CJ (2007) Monoclonal antibody treatment for West Nile virus infection in mice. J Infect Dis 188: 95–112.
101. Valdes I, Bernardo L, Gil L, Pavon A, Lazo L, et al. (2009) A novel fusion-loop specific antibody. EMBO J 28: 3269–3276.
102. Harlow E, Lane D (1988) Antibodies, A laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press. pp 495–516.
103. Minor W, Cymborowski M, Otwinowski Z, Chruszcz M (2006) HKL-3000: the multiple function crystallographic software. J Appl Crystallogr 40: 658–674.
105. Jones EY, Walker NP, Stuart DI (1991) Methodology employed for the structure determination of tumour necrosis factor, a case of high non-crystallographic symmetry. Acta Crystallogr A 47 (Pt 6): 753–770.
106. Winn MD, Murshudov GN, Papiz MZ (2003) Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol 374: 300–321.
107. Shindyalov IN, Bourne PE (1998) Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Eng 11: 739–747.
108. Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15: 553–557.
109. Boder ET, Wittrup KD (1998) Optimal screening of surface-displayed polypeptide libraries. Biotechnol Prog 14: 55–62.
110. Potterton L, McNicholas S, Krissinel E, Gruber J, Cowtan K, et al. (2004) Developments in the CCP4 molecular-graphics project. Acta Crystallogr D Biol Crystallogr 60: 2288–2294.
111. Barton GJ (1993) ALSCRIPT: a tool to format multiple sequence alignments. Protein Eng 6: 37–46.
112. Kabsch W, Sander C (1983) Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22: 2577–2637.